{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:45:25Z","timestamp":1790628325878,"version":"4.1.0"},"reference-count":130,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The interleukin-1 (IL-1) family is involved in the correct functioning and regulation of the innate immune system, linking innate and adaptative immune responses. This complex family is composed by several cytokines, receptors, and co-receptors, all working in a balanced way to maintain homeostasis. Dysregulation of these processes results in tissue inflammation and is involved in the pathogenesis of common inflammatory dermatoses such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. Therefore, therapeutic targeting of IL-1 pathways has been studied, and several monoclonal antibodies are currently being assessed in clinical trials. So far, promising results have been obtained with anti-IL-36R spesolimab and imsidolimab in pustular psoriasis, and their efficacy is being tested in other conditions.<\/jats:p>","DOI":"10.3390\/ijms23169479","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T21:30:34Z","timestamp":1661203834000},"page":"9479","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-5521","authenticated-orcid":false,"given":"Helena","family":"Iznardo","sequence":"first","affiliation":[{"name":"Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Lu\u00eds","family":"Puig","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, 08041 Barcelona, Spain"},{"name":"Institut d\u2019Investigaci\u00f3 Biom\u00e8dica Sant Pau (IIB SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Boutet, M.-A., Nerviani, A., and Pitzalis, C. (2019). IL-36, IL-37, and IL-38 Cytokines in Skin and Joint Inflammation: A Comprehensive Review of Their Therapeutic Potential. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061257"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/eji.201848056","article-title":"Current Perspectives on the Interleukin-1 Family as Targets for Inflammatory Disease","volume":"49","author":"Giannoudaki","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"42594","DOI":"10.1074\/jbc.M111.267922","article-title":"Interleukin-36 (IL-36) Ligands Require Processing for Full Agonist (IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3) or Antagonist (IL-36Ra) Activity","volume":"286","author":"Towne","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1515\/hsz-2016-0215","article-title":"IL-1 Family Cytokines in Cancer Immunity\u2014A Matter of Life and Death","volume":"397","author":"Mora","year":"2016","journal-title":"Biol. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41423-020-0519-3","article-title":"\u201cAutoinflammatory Psoriasis\u201d-Genetics and Biology of Pustular Psoriasis","volume":"18","author":"Uppala","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"155890","DOI":"10.1016\/j.cyto.2022.155890","article-title":"The IL-1 Cytokine Family as Custodians of Barrier Immunity","volume":"154","author":"Matarazzo","year":"2022","journal-title":"Cytokine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 Family in Innate Inflammation and Acquired Immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.4049\/jimmunol.1402155","article-title":"IL-1 Receptor Type 2 Suppresses Collagen-Induced Arthritis by Inhibiting IL-1 Signal on Macrophages","volume":"194","author":"Shimizu","year":"2015","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.immuni.2013.01.008","article-title":"Intracellular Interleukin-1 Receptor 2 Binding Prevents Cleavage and Activity of Interleukin-1\u03b1, Controlling Necrosis-Induced Sterile Inflammation","volume":"38","author":"Zheng","year":"2013","journal-title":"Immunity"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3389\/fimmu.2019.01412","article-title":"Structural Basis of IL-1 Family Cytokine Signaling","volume":"10","author":"Fields","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2013.00289","article-title":"Interleukin-18 and IL-18 Binding Protein","volume":"4","author":"Dinarello","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni.3103","article-title":"IL-37 Requires the Receptors IL-18R\u03b1 and IL-1R8 (SIGIRR) to Carry out Its Multifaceted Anti-Inflammatory Program upon Innate Signal Transduction","volume":"16","author":"Lo","year":"2015","journal-title":"Nat. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/ni.3503","article-title":"Interleukin 1\u03b1 and the Inflammatory Process","volume":"17","author":"Shayakhmetov","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.molcel.2011.07.037","article-title":"Granzyme B-Dependent Proteolysis Acts as a Switch to Enhance the Proinflammatory Activity of IL-1\u03b1","volume":"44","author":"Afonina","year":"2011","journal-title":"Mol. Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27758","DOI":"10.1074\/jbc.270.46.27758","article-title":"Differential Sensitivity of Interleukin-1 Alpha and -Beta Precursor Proteins to Cleavage by Calpain, a Calcium-Dependent Protease","volume":"270","author":"Kavita","year":"1995","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/cmi.2016.34","article-title":"HMGB1, IL-1\u03b1, IL-33 and S100 Proteins: Dual-Function Alarmins","volume":"14","author":"Bertheloot","year":"2017","journal-title":"Cell Mol. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.immuni.2019.03.012","article-title":"Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity","volume":"50","author":"Mantovani","year":"2019","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/5584_2020_488","article-title":"Interleukin-36: Structure, Signaling and Function","volume":"2020","author":"Zhou","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1002\/art.24959","article-title":"Caspase 1-Independent Activation of Interleukin-1beta in Neutrophil-Predominant Inflammation","volume":"60","author":"Guma","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s41590-019-0467-1","article-title":"IL-1R3 Blockade Broadly Attenuates the Functions of Six Members of the IL-1 Family, Revealing Their Contribution to Models of Disease","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.12616","article-title":"Interleukin-18: Biological Properties and Role in Disease Pathogenesis","volume":"281","author":"Kaplanski","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Yasuda, K., Nakanishi, K., and Tsutsui, H. (2019). Interleukin-18 in Health and Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030649"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1002\/1521-4141(200011)30:11<3147::AID-IMMU3147>3.0.CO;2-J","article-title":"IL-18 Induces the Differentiation of Th1 or Th2 Cells Depending upon Cytokine Milieu and Genetic Background","volume":"30","author":"Xu","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s00262-020-02553-4","article-title":"IL-12 Regulates the Expansion, Phenotype, and Function of Murine NK Cells Activated by IL-15 and IL-18","volume":"69","author":"Oka","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2020.04.044","article-title":"Glucocorticoids and the Cytokines IL-12, IL-15, and IL-18 Present in the Tumor Microenvironment Induce PD-1 Expression on Human Natural Killer Cells","volume":"147","author":"Quatrini","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"13962","DOI":"10.1073\/pnas.96.24.13962","article-title":"IL-18, Although Antiallergic When Administered with IL-12, Stimulates IL-4 and Histamine Release by Basophils","volume":"96","author":"Yoshimoto","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CM9.0000000000000140","article-title":"Interleukin-18 Exacerbates Skin Inflammation and Affects Microabscesses and Scale Formation in a Mouse Model of Imiquimod-Induced Psoriasis","volume":"132","author":"Niu","year":"2019","journal-title":"Chin. Med. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/imr.12619","article-title":"Interleukin-33 (IL-33): A Nuclear Cytokine from the IL-1 Family","volume":"281","author":"Cayrol","year":"2018","journal-title":"Immunol. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eabc6259","DOI":"10.1126\/sciimmunol.abc6259","article-title":"Cellular Context of IL-33 Expression Dictates Impact on Anti-Helminth Immunity","volume":"5","author":"Hung","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_30","first-page":"7158014","article-title":"Possible Roles of IL-33 in the Innate-Adaptive Immune Crosstalk of Psoriasis Pathogenesis","volume":"2019","author":"Bertino","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 Amplifies Both Th1- and Th2-Type Responses through Its Activity on Human Basophils, Allergen-Reactive Th2 Cells, INKT and NK Cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109773","DOI":"10.1016\/j.cellsig.2020.109773","article-title":"IL-36 Family Cytokines in Protective versus Destructive Inflammation","volume":"75","author":"Han","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1111\/febs.14075","article-title":"Neutrophil Extracellular Traps Can Serve as Platforms for Processing and Activation of IL-1 Family Cytokines","volume":"284","author":"Clancy","year":"2017","journal-title":"FEBS J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.celrep.2018.02.062","article-title":"Extracellular Neutrophil Proteases Are Efficient Regulators of IL-1, IL-33, and IL-36 Cytokine Activity but Poor Effectors of Microbial Killing","volume":"22","author":"Clancy","year":"2018","journal-title":"Cell Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.celrep.2015.12.072","article-title":"Neutrophil-Derived Proteases Escalate Inflammation through Activation of IL-36 Family Cytokines","volume":"14","author":"Henry","year":"2016","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","article-title":"IL-1 and IL-36 Are Dominant Cytokines in Generalized Pustular Psoriasis","volume":"140","author":"Johnston","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"109705","DOI":"10.1016\/j.biopha.2019.109705","article-title":"The Role of IL-37 in Skin and Connective Tissue Diseases","volume":"122","author":"Pan","year":"2020","journal-title":"Biomed. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Conti, P., Pregliasco, F.E., Bellomo, R.G., Gallenga, C.E., Caraffa, A., Kritas, S.K., Lauritano, D., and Ronconi, G. (2021). Mast Cell Cytokines IL-1, IL-33, and IL-36 Mediate Skin Inflammation in Psoriasis: A Novel Therapeutic Approach with the Anti-Inflammatory Cytokines IL-37, IL-38, and IL-1Ra. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158076"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.celrep.2019.03.082","article-title":"IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from \u0393\u03b4 T Cells","volume":"27","author":"Han","year":"2019","journal-title":"Cell Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/jdv.14386","article-title":"European Consensus Statement on Phenotypes of Pustular Psoriasis","volume":"31","author":"Navarini","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An Update on Generalized Pustular Psoriasis","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"155897","DOI":"10.1016\/j.cyto.2022.155897","article-title":"Role of IL-36 Cytokines in Psoriasis and Other Inflammatory Skin Conditions","volume":"156","author":"Sachen","year":"2022","journal-title":"Cytokine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1365-2133.2010.09662.x","article-title":"Interleukin-1 from Epithelial Cells Fosters T Cell-Dependent Skin Inflammation","volume":"162","author":"Renne","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A Critical Role of the IL-1\u03b2-IL-1R Signaling Pathway in Skin Inflammation and Psoriasis Pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"29357","DOI":"10.3390\/ijms161226172","article-title":"IL-18 and Cutaneous Inflammatory Diseases","volume":"16","author":"Lee","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00403-017-1735-2","article-title":"Interleukin (IL)-18, Cooperatively with IL-23, Induces Prominent Inflammation and Enhances Psoriasis-like Epidermal Hyperplasia","volume":"309","author":"Shimoura","year":"2017","journal-title":"Arch. Dermatol. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jid.2020.07.027","article-title":"An Autocrine Circuit of IL-33 in Keratinocytes Is Involved in the Progression of Psoriasis","volume":"141","author":"Zeng","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/ced.12670","article-title":"Serum IL-33 Levels Are Increased in Patients with Psoriasis","volume":"41","author":"Mitsui","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-Receptor Antagonist Deficiency and Generalized Pustular Psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_51","first-page":"179","article-title":"Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris","volume":"17","author":"Sehat","year":"2018","journal-title":"Iran. J. Allergy Asthma Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41419-018-1143-3","article-title":"IL-38 Has an Anti-Inflammatory Action in Psoriasis and Its Expression Correlates with Disease Severity and Therapeutic Response to Anti-IL-17A Treatment","volume":"9","author":"Mercurio","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"732790","DOI":"10.3389\/fphar.2021.732790","article-title":"The Pathological Mechanism and Potential Application of IL-38 in Autoimmune Diseases","volume":"12","author":"Han","year":"2021","journal-title":"Front. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Xie, L., Huang, Z., Li, H., Liu, X., Zheng, S., and Su, W. (2019). IL-38: A New Player in Inflammatory Autoimmune Disorders. Biomolecules, 9.","DOI":"10.3390\/biom9080345"},{"key":"ref_55","first-page":"1019","article-title":"Mesenchymal Stem Cells and IL-37: A Powerful Combination","volume":"33","author":"Gugliandolo","year":"2019","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","article-title":"The Atopic March and Atopic Multimorbidity: Many Trajectories, Many Pathways","volume":"143","author":"Paller","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1248\/bpb.b19-00088","article-title":"Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus","volume":"43","author":"Fujii","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/exd.13911","article-title":"Understanding the Immune Landscape in Atopic Dermatitis: The Era of Biologics and Emerging Therapeutic Approaches","volume":"28","author":"Moyle","year":"2019","journal-title":"Exp. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/1744666X.2020.1858802","article-title":"Therapeutic Targeting of the IL-13 Pathway in Skin Inflammation","volume":"17","author":"Tubau","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdermsci.2010.02.008","article-title":"Extrinsic and Intrinsic Types of Atopic Dermatitis","volume":"58","author":"Tokura","year":"2010","journal-title":"J. Dermatol. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jaci.2013.04.046","article-title":"Intrinsic Atopic Dermatitis Shows Similar TH2 and Higher TH17 Immune Activation Compared with Extrinsic Atopic Dermatitis","volume":"132","author":"Dhingra","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"143334","DOI":"10.1172\/JCI143334","article-title":"Epicutaneous Staphylococcus Aureus Induces IL-36 to Enhance IgE Production and Ensuing Allergic Disease","volume":"131","author":"Patrick","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10875-019-00622-7","article-title":"Interleukin-36 Receptor Antagonist Deficiency (DITRA) with a Novel IL36RN Homozygous Mutation c.200G\u2009>\u2009T (P.Cys67Phe) in a Young Colombian Woman","volume":"39","author":"Vargas","year":"2019","journal-title":"J. Clin. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2014.01.867","article-title":"Increased Serum Levels of Interleukin 33 in Patients with Atopic Dermatitis","volume":"70","author":"Okuzawa","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jaci.2013.03.050","article-title":"Human IL-31 Is Induced by IL-4 and Promotes TH2-Driven Inflammation","volume":"132","author":"Stott","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","article-title":"Progression of Acute-to-Chronic Atopic Dermatitis Is Associated with Quantitative Rather than Qualitative Changes in Cytokine Responses","volume":"145","author":"Tsoi","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/exd.12967","article-title":"Distinct Molecular Signatures of Mild Extrinsic and Intrinsic Atopic Dermatitis","volume":"25","author":"Martel","year":"2016","journal-title":"Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.7150\/ijms.20809","article-title":"IL-36\u03b3 Inhibits Differentiation and Induces Inflammation of Keratinocyte via Wnt Signaling Pathway in Psoriasis","volume":"14","author":"Wang","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/jdv.16677","article-title":"Hidradenitis Suppurativa: An Update on Epidemiology, Phenotypes, Diagnosis, Pathogenesis, Comorbidities and Quality of Life","volume":"35","author":"Nguyen","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis Suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/bjd.19538","article-title":"Identifying Key Components and Therapeutic Targets of the Immune System in Hidradenitis Suppurativa with an Emphasis on Neutrophils","volume":"184","author":"Narla","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction","volume":"139","author":"Wolk","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjd.19795","article-title":"Activity and Components of the Granulocyte Colony-Stimulating Factor Pathway in Hidradenitis Suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased Expression of the Interleukin-36 Cytokines in Lesions of Hidradenitis Suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in Hidradenitis Suppurativa: Evidence for a Distinctive Proinflammatory Role and a Key Factor in the Development of an Inflammatory Loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00403-017-1769-5","article-title":"IL-36 Cytokines Are Increased in Acne and Hidradenitis Suppurativa","volume":"309","author":"Balato","year":"2017","journal-title":"Arch Dermatol. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00403-019-02012-w","article-title":"Serum IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3 Levels in Patients with Hidradenitis Suppurativa: Association with Disease Characteristics, Smoking, Obesity, and Metabolic Syndrome","volume":"312","author":"Hayran","year":"2020","journal-title":"Arch Dermatol. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/exd.12272","article-title":"The Balance between Pro- and Anti-Inflammatory Cytokines Is Crucial in Human Allergic Contact Dermatitis Pathogenesis: The Role of IL-1 Family Members","volume":"22","author":"Mattii","year":"2013","journal-title":"Exp. Dermatol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3389\/fimmu.2019.01059","article-title":"Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases","volume":"10","author":"Marzano","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000371879","article-title":"Severe Sweet\u2019s Syndrome with Elevated Cutaneous Interleukin-1\u03b2 after Azathioprine Exposure: Case Report and Review of the Literature","volume":"230","author":"Imhof","year":"2015","journal-title":"Dermatology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1111\/bjd.14037","article-title":"Canakinumab in Adults with Steroid-Refractory Pyoderma Gangrenosum","volume":"173","author":"Kolios","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jid.2018.10.023","article-title":"Culprit Drugs Induce Specific IL-36 Overexpression in Acute Generalized Exanthematous Pustulosis","volume":"139","author":"Feldmeyer","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/14740338.2020.1785427","article-title":"Biologics in the Treatment of Pustular Psoriasis","volume":"19","author":"Wang","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/bjd.20975","article-title":"Therapeutic Potential of Targeting Interleukin-1 Family Cytokines in Chronic Inflammatory Skin Diseases","volume":"186","author":"Calabrese","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjd.20653","article-title":"Anakinra for Palmoplantar Pustulosis: Results from a Randomized, Double-Blind, Multicentre, Two-Staged, Adaptive Placebo-Controlled Trial (APRICOT)","volume":"186","author":"Cro","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An Open-Label Study of Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol."},{"key":"ref_89","first-page":"e208","article-title":"Long-Term Therapy with Anakinra in Hidradenitis Suppurativa in Three Patients","volume":"58","author":"Marescassier","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_90","unstructured":"Edward Cowen, M.D. (2022, June 23). A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01794117."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain","volume":"140","author":"Gottlieb","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 Targeting IL-1\u03b1 for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study","volume":"138","author":"Kanni","year":"2018","journal-title":"J. Investig. Dermatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ced.14333","article-title":"MABp1 Targeting Interleukin-1\u03b1 in Hidradenitis Suppurativa Ineligible for Adalimumab Treatment: Results of the Open-Label Extension Period","volume":"46","author":"Kanni","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_94","unstructured":"Janssen Research & Development, LLC (2022, June 23). A Phase 2a\/2b, Multicenter, Randomized, Placebo and Active Comparator-Controlled, Double-Blind, Dose-Ranging Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04988308."},{"key":"ref_95","first-page":"560","article-title":"An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity","volume":"14","author":"Carrasco","year":"2015","journal-title":"J. Drugs Dermatol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamadermatol.2014.5391","article-title":"Open-Label Trial of MABp1, a True Human Monoclonal Antibody Targeting Interleukin 1\u03b1, for the Treatment of Psoriasis","volume":"151","author":"Coleman","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_97","unstructured":"Janssen Research & Development, LLC (2022, June 23). A Phase 2a, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Interventional Study to Assess the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Multiple IV Doses of Bermekimab for the Treatment of Adult Participants with Moderate-to-Severe Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04021862."},{"key":"ref_98","unstructured":"Janssen Research & Development, LLC (2022, June 23). A Phase 2b, Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants with Moderate to Severe Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04791319."},{"key":"ref_99","first-page":"36","article-title":"Non-Response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa","volume":"10","author":"Sun","year":"2017","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","article-title":"Canakinumab for Severe Hidradenitis Suppurativa: Preliminary Experience in 2 Cases","volume":"153","author":"Houriet","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjd.14685","article-title":"Successful Response in a Case of Severe Pustular Psoriasis after Interleukin-1\u03b2 Inhibition","volume":"176","author":"Skendros","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/ced.12759","article-title":"Palmoplantar Pustular Psoriasis Unresponsive to the Interleukin-1\u03b2 Antagonist Canakinumab","volume":"41","author":"Mansouri","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_103","first-page":"840","article-title":"Open-Label, Multicentre, Dose-Escalating Phase II Clinical Trial on the Safety and Efficacy of Tadekinig Alfa (IL-18BP) in Adult-Onset Still\u2019s Disease","volume":"77","author":"Gabay","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaax2945","DOI":"10.1126\/scitranslmed.aax2945","article-title":"Proof-of-Concept Clinical Trial of Etokimab Shows a Key Role for IL-33 in Atopic Dermatitis Pathogenesis","volume":"11","author":"Chen","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_105","unstructured":"AnaptysBio, Inc. (2022, June 23). A Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Investigate Etokimab (ANB020) in Adult Subjects with Chronic Rhinosinusitis with Nasal Polyposis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03614923."},{"key":"ref_106","unstructured":"Regeneron Pharmaceuticals (2022, June 23). A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients with Moderate-to-Severe Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03736967."},{"key":"ref_107","unstructured":"Regeneron Pharmaceuticals (2022, June 23). A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients with Moderate-to- Severe Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03738423."},{"key":"ref_108","unstructured":"Pfizer (2022, June 23). A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and\/or Multiple Intravenous and\/or Subcutaneous Doses of Pf-06817024 in Healthy Subjects Who May Be Mildly Atopic, Subjects with Chronic Rhinosinusitis with Nasal Polyps, and Subjects with Moderate-Severe Atopic Dermatitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01989143."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1111\/bcp.14361","article-title":"The First-in-Human Study of CNTO 7160, an Anti-Interleukin-33 Receptor Monoclonal Antibody, in Healthy Subjects and Patients with Asthma or Atopic Dermatitis","volume":"86","author":"Nnane","year":"2020","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of Spesolimab for Generalized Pustular Psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","article-title":"Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase Iia, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study","volume":"11","author":"Mrowietz","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_113","unstructured":"Boehringer Ingelheim (2022, July 04). Randomized, Double-Blind, Placebo-Controlled, Study of Spesolimab in Patients with Moderate to Severe Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04762277."},{"key":"ref_114","unstructured":"Boehringer Ingelheim (2022, July 04). An Open-Label, Long-Term Extension Trial of Spesolimab Treatment in Adult Patients with Hidradenitis Suppurativa (HS), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04876391."},{"key":"ref_115","unstructured":"Boehringer Ingelheim (2022, July 04). Multi-Centre, Open-Label, Expanded Access Trial of Spesolimab i.v. in Patients with Generalized Pustular Psoriasis (GPP) Presenting with a Flare, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05200247."},{"key":"ref_116","unstructured":"Boehringer Ingelheim (2022, July 04). Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Phase IIa Trial to Evaluate Spesolimab (BI 655130) Efficacy in Patients with Fibrostenotic Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05013385."},{"key":"ref_117","unstructured":"Boehringer Ingelheim (2022, July 04). An Open Label, Long Term Safety Trial of Spesolimab Treatment in Patients with Fistulising Crohn\u2019s Disease Who Have Completed Previous Spesolimab Trials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04362254."},{"key":"ref_118","unstructured":"Boehringer Ingelheim (2022, July 04). A Phase II\/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI655130 (SPESOLIMAB) Induction Therapy in Patients with Moderate-to-Severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03482635."},{"key":"ref_119","unstructured":"Boehringer Ingelheim (2022, July 04). An Open Label, Long Term Safety Trial of BI 65513 (SPESOLIMAB) Treatment in Patients with Moderate to Severely Active Ulcerative Colitis Who Have Completed Previous BI 655130 Trials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03648541."},{"key":"ref_120","unstructured":"Boehringer Ingelheim (2022, July 04). EffisayilTM 2: Multi-Center, Randomized, Parallel Group, Double Blind, Placebo Controlled, Phase IIb Dose-Finding Study to Evaluate Efficacy and Safety of BI 655130 (Spesolimab) Compared to Placebo in Preventing Generalized Pustular Psoriasis (GPP) Flares in Patients with History of GPP, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04399837."},{"key":"ref_121","unstructured":"Boehringer Ingelheim (2022, July 04). An Open-Label, Long Term Safety Trial of Spesolimab Treatment in Patients with Palmoplantar Pustulosis (PPP) Who Have Completed Previous BI Spesolimab Trials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04493424."},{"key":"ref_122","unstructured":"AnaptysBio, Inc. (2022, January 17). AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint. Available online: https:\/\/ir.anaptysbio.com\/news-releases\/news-release-details\/anaptysbio-reports-imsidolimab-poplar-phase-2-clinical-trial\/."},{"key":"ref_123","unstructured":"AnaptysBio, Inc. (2022, July 04). A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03633396."},{"key":"ref_124","unstructured":"AnaptysBio, Inc. (2022, July 04). A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects with Generalized Pustular Psoriasis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619902."},{"key":"ref_125","unstructured":"AnaptysBio, Inc. (2022, July 04). A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05352893."},{"key":"ref_126","unstructured":"AnaptysBio, Inc. (2022, July 04). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized Pustular Psoriasis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05366855."},{"key":"ref_127","unstructured":"AnaptysBio, Inc. (2022, July 04). A Phase 2, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects with Hidradenitis Suppurativa, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04856930."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-2094-11-27","article-title":"Anti-Inflammatory Properties of a Novel Peptide Interleukin 1 Receptor Antagonist","volume":"11","author":"Klementiev","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"9089","DOI":"10.1038\/s41598-019-45626-w","article-title":"Small Molecule IL-36\u03b3 Antagonist as a Novel Therapeutic Approach for Plaque Psoriasis","volume":"9","author":"Su","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/bjd.20944","article-title":"Response to: \u201cAnakinra for Palmoplantar Pustulosis: Results from a Randomized, Double-Blind, Multicentre, Two-Staged, Adaptive Placebo-Controlled Trial (APRICOT)\u201d: Reply from the Authors","volume":"186","author":"Cro","year":"2022","journal-title":"Br. J. Dermatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9479\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:13:31Z","timestamp":1760141611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/16\/9479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,22]]},"references-count":130,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23169479"],"URL":"https:\/\/doi.org\/10.3390\/ijms23169479","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,22]]}}}